Comparison guide

US vs EU: two different compliance worlds.

American brands entering Europe, and European brands entering America, both make the same mistake: assuming the other side works like home. It does not. The US regulates facilities and honesty; the EU regulates products and proof. Here is the whole divide, mapped.

Reviewed by Cassandra Maddocks, chemist & biochemist · last reviewed 27 July 2026

How do US and EU cosmetic rules differ?

The EU is pre-market: before sale you need a Responsible Person, a signed safety report, a Product Information File and a CPNP notification per product. The US under MoCRA is registration-based: facilities register, products are listed, safety is substantiated on file, and nothing is reviewed before launch in either system.

United States and European Union compared
	United States	European Union
Legal basis	FDCA and MoCRA	Regulation (EC) No 1223/2009
Before first sale	Facility registration and product listing (within 120 days)	RP appointed, CPSR signed, PIF assembled, CPNP filed
Named responsible party	Responsible person on the label, US Agent for foreign facilities	EU-established Responsible Person on the label
Safety evidence	Adequate substantiation kept on file, format free	CPSR in the Annex I format, signed by a qualified assessor
Small-business relief	Under $1M average US sales: exempt from registration and listing	None; a hobbyist carries the same duties as a multinational
Label extras	Adverse-event contact required since 29 Dec 2024	Article 19 particulars, INCI, RP address, PAO or best-before
Is anything approved?	No; FDA issues no certificates for registration or listing	No; notification is a record, not an approval

Primary texts: the FDA's MoCRA page and Regulation (EC) No 1223/2009.

Does my US safety documentation work in the EU?

No. A US-format safety report does not transfer: the EU requires a Cosmetic Product Safety Report in the Annex I structure, signed by an assessor with recognised EU qualifications. The underlying test data usually carries over; the assessment itself has to be rebuilt and re-signed.

This is the single most expensive surprise for US brands entering Europe. The data you already hold (stability, challenge, micro results) feeds straight into the CPSR inputs, so the rebuild is usually a matter of $450 to $600 per product rather than a new lab programme.

Article 10 of Regulation 1223/2009 on EUR-Lex with the safety assessment requirement highlighted — Article 10(1) of Regulation (EC) No 1223/2009, the safety assessment duty a US report cannot satisfy, as published on EUR-Lex, consolidation of 1 May 2026 (02009R1223, EN, 040.001). Captured 26 July 2026. View the official text.

Does my EU compliance help me in the US?

Substantially. A brand with a complete PIF already holds more safety evidence than MoCRA's substantiation duty demands, and EU labels need only the US-specific additions such as the adverse-event contact. What the EU file cannot do is register your facility or list your products; those are separate filings.

The direction of travel matters: EU-to-US is mostly administrative ($900 for registration and listing setup), while US-to-EU means building the evidence chain the EU expects. The mechanics live in our MoCRA guide and EU guide.

The FDA registration and listing page with the biennial facility registration requirement highlighted — The FDA's Registration and Listing page, the filings an EU dossier cannot replace. Captured 26 July 2026. View the official text.

Why does the EU ban so many more ingredients?

Annex II of the EU regulation prohibits more than 1,700 substances and grows several times a year as newly classified CMR substances are added. The FDA's own prohibited and restricted list runs to roughly a dozen entries. The gap reflects philosophy: the EU screens ingredients up front, the US intervenes after harm is shown.

This is the statistic behind most clean beauty marketing, and it cuts both ways: an EU-compliant formula usually clears the US ingredient bar automatically, while a US formula needs a line-by-line check against the annexes. The entries themselves, retinol to hydroquinone, are captured in our ingredient rules guide; the FDA's short list is on its prohibited ingredients page.

Why are sunscreens a special case?

Because the two systems classify them differently: in the EU a sunscreen is a cosmetic under Regulation 1223/2009, while in the US it is an over-the-counter drug with its own monograph, approval-style requirements and a much shorter list of permitted UV filters. The same product can be a cosmetic on one side of the Atlantic and a drug on the other.

The practical consequences are famous: the EU permits roughly twice as many UV filters as the US, which is why modern European sun care often cannot be sold in America unchanged. Any brand with an SPF product should treat the US as a separate regulatory project, not a labelling tweak; tell us about it in a quote request before committing to artwork.

Which market is harder to enter?

The EU, by design: it front-loads the work before the first unit sells. The US spreads obligations out but polices honesty harder, with the FTC and FDA acting on claims. A brand compliant in both typically built the EU file first and reused it westward.

For a brand doing both at once, the arithmetic is one EU and UK launch pack plus a MoCRA setup, $2,400 per product all in; the full breakdown is in our cost guide. For your own range, request a quote.

Sources

Primary sources cited in this guide. Regulatory status last verified 27 July 2026.